levofloxacin has been researched along with Pyelonephritis in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (10.34) | 18.2507 |
| 2000's | 13 (44.83) | 29.6817 |
| 2010's | 11 (37.93) | 24.3611 |
| 2020's | 2 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Naber, KG; Redman, R; Wagenlehner, C; Wagenlehner, FM; Weidner, W | 1 |
| Hedrich, D; Kaniga, K; Kotey, P; Llorens, L; Naber, KG; Redman, R | 1 |
| Bientinesi, R; Murri, R; Sacco, E | 1 |
| Abolghasemi, S; Elyasi, F; Tehrani, S | 1 |
| Huntington, JA; Long, J; Popejoy, MW | 1 |
| Armstrong, ES; Cebrik, D; Connolly, LE; Miller, LG; Riddle, V | 1 |
| Debrix, I; Hertig, A; Rafat, C | 1 |
| Darouiche, RO; Steenbergen, J; Umeh, O; Wagenlehner, FM; Yuan, G | 1 |
| Garland, JL; Lewis, JI; Squier, SB | 1 |
| Geerlings, SE; Holleman, F; Schneeberger, C | 1 |
| Cao, B; Cen, J; Chen, N; Cheng, H; Hu, Y; Li, X; Li, YF; Liu, YH; Ni, ZH; Niu, JY; Qiu, XH; Ren, AM; Ren, H; Tu, XW; Xing, CY; Xu, J; Xu, XD; Zhou, R | 1 |
| Al-Hasan, MN; Albrecht, H; Bookstaver, PB; Justo, JA; Kohn, J; Shah, A | 1 |
| Abrahamian, FM; Krishnadasan, A; Moran, GJ; Stamm, WE; Talan, DA | 1 |
| Davila, G; De Castro, F; Rojas, P; Ruiz-Hornillos, J; Zubeldia, JM | 1 |
| Mirone, V | 1 |
| Bai, C; Huang, W; Mei, C; Wang, J; Xiao, Y; Xiu, Q; Xu, N; Zheng, Q | 1 |
| Damiao, R; Davies, T; Kaniga, K; Kotey, P; Naber, KG; Redman, R | 1 |
| Hayasaka, T; Saito, T; Tsuruoka, S; Yamagata, K; Yokota, N | 1 |
| Tash, K | 1 |
| Hiyama, L; Miller, LG; Tang, A | 1 |
| Brown, P; Fisher, AC; Kahn, JB; Kaul, S; Khashab, M; Klausner, HA; Peterson, J | 1 |
| Dib-Smahi, C; Lascols, C; Soussy, CJ | 1 |
| Fisher, A; Kahn, JB; Kaul, S; Khashab, M; Peterson, J | 1 |
| Bryski, L; Duckworth, H; Harding, G; Nicolle, L; Sitar, D; Zhanel, G | 1 |
| Fisher, AC; Kahn, JB; Kaul, S; Khashab, M; Peterson, J | 1 |
| Geweniger, KH; Isert, D; Iyer, P; Klesel, N; Koletzki, P; Limbert, M; Markus, A; Riess, G; Schramm, H | 1 |
| Barrett, JF; Frosco, MB; Kulwich, BA; Licata, L; Melton, JL; Stewart, FP | 1 |
| Callery-D'Amico, S; Fowler, CL; Kim, SS; Klimberg, IN; Richard, GA | 1 |
| Fujita, K; Hadano, S; Kambayashi, T; Mizuno, T; Mugiya, S; Nakano, M; Satoh, S; Suzuki, K; Ushiyama, T | 1 |
4 review(s) available for levofloxacin and Pyelonephritis
| Article | Year |
|---|---|
Efficacy and safety of levofloxacin as a treatment for complicated urinary tract infections and pyelonephritis.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Female; Humans; Infection Control; Levofloxacin; Pyelonephritis; Sepsis; Urinary Tract Infections | 2020 |
Levofloxacin for the treatment of pyelonephritis.
Topics: Administration, Oral; Ambulatory Care; Anti-Bacterial Agents; Drug Resistance, Bacterial; Humans; Levofloxacin; Practice Guidelines as Topic; Pyelonephritis; Urinary Tract Infections | 2013 |
Febrile urinary tract infections: pyelonephritis and urosepsis.
Topics: Anti-Infective Agents, Urinary; Cephalosporins; Diabetes Complications; Fever; Humans; Immunocompromised Host; Levofloxacin; Penicillanic Acid; Pyelonephritis; Randomized Controlled Trials as Topic; Risk Factors; Sepsis; Tazobactam; Treatment Outcome; Urinary Tract Infections | 2016 |
[From cystitis to bacterial prostatitis: experience with levofloxacin].
Topics: Anti-Bacterial Agents; Bacterial Infections; Cystitis; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levofloxacin; Male; Multicenter Studies as Topic; Ofloxacin; Practice Guidelines as Topic; Prostatitis; Pyelonephritis; Randomized Controlled Trials as Topic; Risk Factors; Urethritis; Urinary Tract Infections | 2009 |
14 trial(s) available for levofloxacin and Pyelonephritis
| Article | Year |
|---|---|
Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Carbapenems; Doripenem; Double-Blind Method; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Prospective Studies; Pyelonephritis; Urinary Tract Infections | 2009 |
Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Carbapenems; Doripenem; Double-Blind Method; Female; Humans; Infusions, Intravenous; Levofloxacin; Male; Ofloxacin; Pyelonephritis; Urinary Tract Infections | 2009 |
Levofloxacin Versus Ceftriaxone for the Treatment of Acute Pyelonephritis in Iranian Adults.
Topics: Adult; Anti-Bacterial Agents; Ceftriaxone; Humans; Iran; Levofloxacin; Pyelonephritis; Urinary Tract Infections | 2021 |
Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Diabetes Complications; Diabetes Mellitus; Female; Humans; Intraabdominal Infections; Levofloxacin; Male; Metronidazole; Middle Aged; Penicillanic Acid; Pyelonephritis; Tazobactam; Urinary Tract Infections | 2017 |
A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis.
Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Double-Blind Method; Female; Humans; Levofloxacin; Male; Middle Aged; Pyelonephritis; Sisomicin; Urinary Tract Infections; Young Adult | 2018 |
Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).
Topics: Adult; Aged; Anti-Infective Agents, Urinary; Cephalosporins; Double-Blind Method; Drug Administration Schedule; Female; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Infusions, Intravenous; Levofloxacin; Male; Middle Aged; Penicillanic Acid; Pyelonephritis; Tazobactam; Treatment Outcome; Urinary Tract Infections; Young Adult | 2015 |
Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-i
Topics: Acute Disease; Administration, Intravenous; Administration, Oral; Adult; Aged; Anti-Infective Agents, Urinary; Female; Humans; Intention to Treat Analysis; Levofloxacin; Male; Middle Aged; Pyelonephritis; Treatment Outcome; Urinary Tract Infections | 2017 |
A phase II study of antofloxacin hydrochloride, a novel fluoroquinolone, for the treatment of acute bacterial infections.
Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; Bronchitis, Chronic; Demography; Double-Blind Method; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pyelonephritis | 2010 |
Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis.
Topics: Aged; Anti-Infective Agents, Urinary; Carbapenems; Doripenem; Double-Blind Method; Female; Genotype; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Injections, Intravenous; Levofloxacin; Male; Middle Aged; Ofloxacin; Pyelonephritis; Treatment Outcome; Urinary Tract Infections | 2010 |
A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis.
Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; Ciprofloxacin; Double-Blind Method; Drug Administration Schedule; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pyelonephritis | 2007 |
Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Ciprofloxacin; Double-Blind Method; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Pyelonephritis; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; United States; Urinary Tract Infections | 2007 |
A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis.
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Double-Blind Method; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pyelonephritis; Treatment Outcome; Urinary Catheterization; Urinary Tract Infections | 2008 |
Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pyelonephritis | 1998 |
Complicating risk factors for pyelonephritis after extracorporeal shock wave lithotripsy.
Topics: Adolescent; Adult; Age Distribution; Aged; Anti-Infective Agents, Urinary; Bacteriuria; Humans; Kidney Calculi; Levofloxacin; Lithotripsy; Middle Aged; Multivariate Analysis; Ofloxacin; Postoperative Complications; Predictive Value of Tests; Pyelonephritis; Risk Factors; Sex Distribution | 2000 |
11 other study(ies) available for levofloxacin and Pyelonephritis
| Article | Year |
|---|---|
63-Year-Old Woman With Generalized Fatigue and Left Flank Pain.
Topics: Acute Disease; Anti-Bacterial Agents; Catheterization, Central Venous; Diagnosis, Differential; Drug Administration Routes; Escherichia coli; Fatigue; Female; Flank Pain; Fluid Therapy; Humans; Levofloxacin; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pyelonephritis; Systemic Inflammatory Response Syndrome; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Application of Fluoroquinolone Resistance Score in Management of Complicated Urinary Tract Infections.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Pyelonephritis; Urinary Tract Infections | 2017 |
Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ciprofloxacin; Cross-Sectional Studies; Drug Resistance, Bacterial; Emergencies; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Humans; Levofloxacin; Middle Aged; Ofloxacin; Pyelonephritis; Risk Factors; Trimethoprim, Sulfamethoxazole Drug Combination; United States | 2008 |
Toxic epidermal necrolysis induced by levofloxacin.
Topics: Fatal Outcome; Female; Humans; Levofloxacin; Middle Aged; Ofloxacin; Pyelonephritis; Stevens-Johnson Syndrome | 2009 |
Pharmacokinetics of multiple-dose levofloxacin in hemodialysis patients.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Half-Life; Humans; Levofloxacin; Middle Aged; Ofloxacin; Pyelonephritis; Renal Dialysis | 2011 |
Rahnella aquatilis bacteremia from a suspected urinary source.
Topics: Aged; Anti-Bacterial Agents; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Levofloxacin; Male; Microbial Sensitivity Tests; Ofloxacin; Prostatic Hyperplasia; Pyelonephritis; Rahnella | 2005 |
Levofloxacin penetration into a renal cyst in a patient with autosomal dominant polycystic kidney disease.
Topics: Adult; Ampicillin; Anti-Bacterial Agents; Biological Availability; Drug Therapy, Combination; Female; Humans; Levofloxacin; Ofloxacin; Polycystic Kidney, Autosomal Dominant; Pyelonephritis; Streptococcal Infections; Streptococcus agalactiae | 2006 |
[In vitro activity of levofloxacin against Escherichia coli strains in acute pyelonephritis, in France in 2005].
Topics: Acute Disease; Anti-Bacterial Agents; Escherichia coli; Escherichia coli Infections; France; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pyelonephritis | 2007 |
Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Area Under Curve; Escherichia coli Infections; Female; Humans; Levofloxacin; Ofloxacin; Pyelonephritis; Serum; Time Factors; Urine | 2008 |
Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals.
Topics: Abscess; Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Female; Granuloma; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Male; Mice; Mice, Inbred C3H; Microbial Sensitivity Tests; Ofloxacin; Pneumonia, Pneumococcal; Pyelonephritis; Rats; Rats, Wistar; Sepsis; Stereoisomerism; Streptococcus pneumoniae | 1995 |
In vivo efficacies of levofloxacin and ciprofloxacin in acute murine hematogenous pyelonephritis induced by methicillin-susceptible and-resistant Staphylococcus aureus strains.
Topics: Acute Disease; Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Female; Kidney; Levofloxacin; Methicillin Resistance; Mice; Ofloxacin; Pyelonephritis; Staphylococcal Infections | 1996 |